Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is characterized as a nonmalignant or premalignant state whereby monoclonal immunoglobulins are detected in plasma, urine, or both. Approximately 3% to 4% of the population over the age of 50 is diagnosed with MGUS. It is estimated that 1% will progress to multiple myeloma or lymphoma over 20 years and therefore require ongoing clinical monitoring. Monoclonal gammopathy of undetermined significance is categorized into three types that are determined by the paraprotein clone: immunoglobulin M (IgM) MGUS, non-IgM MGUS, and light chain MGUS. There are high-risk genetic, biochemical, and clinical factors that increase the risk of transformation to multiple myeloma or lymphoma. The incidence of MGUS is two- to threefold higher in the Black population compared with the White population, along with an earlier age of onset. Familial risk and modifiable lifestyle factors are also associated with the development of MGUS and multiple myeloma. Certain monoclonal gammopathies, known as monoclonal gammopathy of clinical significance (MGCS), are associated with various organs that are involved (kidney, brain, skin, lungs, liver, eyes, and heart). The most common MGCS are associated with renal and neurological abnormalities, and treatment may be considered. Early diagnosis and multidisciplinary approaches to mitigate organ damage and other complications are important for the recognition and management of MGCS. Monoclonal gammopathy of undetermined significance is monitored rather than treated unless there are clinical findings of progression or organ dysfunction. Ongoing research and clinical trials are essential to refine monitoring guidelines, develop targeted therapies, and explore preventive measures aimed at reducing progression to multiple myeloma and other malignancies.
References
Abeykoon, J. P., Tawfiq, R. K., Kumar, S., & Ansell, S. M. (2022). Monoclonal gammopathy of undetermined significance: Evaluation, risk assessment, management, and beyond. Faculty Reviews, 11, 34. https://doi.org/10.12703/r/11-34
Atkin, C., Richter, A., & Sapey, E. (2018). What is the significance of monoclonal gammopathy of undetermined significance? Clinical Medicine, 18(5), 391–396. https://doi.org/10.7861/clinmedicine.18-5-391
Berenson, J. R., Anderson, K. C., Audell, R. A., Boccia, R. V., Coleman, M., Dimopoulos, M. A., Drake, M. T., Fonseca, R., Harousseau, J.-L., Joshua, D., Lonial, S., Niesvizky, R., Palumbo, A., Roodman, G. D., San Miguel, J. F., Singhal, S., Weber, D. M., Zangari, M., Wirtschafter, E., Yellin, O.,…Kyle, R. A. (2010). Monoclonal gammopathy of undetermined significance: A consensus statement. British Journal of Haematology, 150(1), 28–38. https://doi.org/10.1111/j.1365-2141.2010.08207.x
Bergstrom, D. J., Kotb, R., Louzada, M. L., Sutherland, H. J., Tavoularis, S., Venner, C. P., & Myeloma Canada Research Network Consensus Guideline Consortium. (2020). Consensus guidelines on the diagnosis of multiple myeloma and related disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clinical Lymphoma, Myeloma & Leukemia, 20(7), e352–e367. https://doi.org/10.1016/j.clml.2020.01.017
Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D’Sa, S., Soutar, R., Waage, A., Gulbrandsen, N., Gregersen, H., Low, E., & Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum, and Nordic Myeloma Study Group. (2009). Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance. British Journal of Haematology, 147(1), 22–42. https://doi.org/10.1111/j.1365-2141.2009.07807.x
Bridoux, F., Leung, N., Hutchison, C. A., Touchard, G., Sethi, S., Fermand, J.-P., Picken, M. M., Herrera, G. A., Kastritis, E., Merlini, G., Roussel, M., Fervenza, F. C., Dispenzieri, A., Kyle, R. A., Nasr, S. H., & International Kidney and Monoclonal Gammopathy Research Group. (2015). Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 87(4), 698–711. https://doi.org/10.1038/ki.2014.408
Castillo, J. J., Callander, N. S., Baljevic, M., Sborov, D. W., & Kumar, S. (2021). The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurologic significance. American Journal of Hematology, 96(7), 846–853. https://doi.org/10.1002/ajh.26155
Chen, L. Y., Drayson, M., Bunce, C., & Ramasamy, K. (2023). Monoclonal gammopathy of increasing significance: Time to screen? Haematologica, 108(6), 1476–1486. https://doi.org/10.3324/haematol.2022.281802
Choudhuri, S., & Rainone, F. (2023). Assessment of current clinical practice throughout the UK for the diagnosis and management of monoclonal gammopathy of renal significance. European Journal of Haematology, 4(2), 410–418. https://doi.org/10.1002/jha2.658
Ciocchini, M., Arbelbide, J., & Musso, C. G. (2017). Monoclonal gammopathy of renal significance (MGRS): The characteristics and significance of a new meta-entity. International Urology and Nephrology, 49(12), 2171–2175. https://doi.org/10.1007/s11255-017-1594-y
Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., Lightbody, E., Downey, K., Argyelan, D., Theodorakakou, F., Fotiou, D., Liacos, C. I., Kanellias, N., Chavda, S. J., Ainley, L., Sandecká, V.,…Ghobrial, I. M. (2023). Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): A retrospective, multicohort study. The Lancet. Haematology, 10(3), e203–e212. https://doi.org/10.1016/S2352-3026(22)00386-6
D’Sa, S., Kersten, M. J., Castillo, J. J., Dimopoulos, M., Kastritis, E., Laane, E., Leblond, V., Merlini, G., Treon, S. P., Vos, J. M., & Lunn, M. P. (2017). Investigation and management of IgM and Waldenström-associated peripheral neuropathies: Recommendations from the IWWM-8 consensus panel. British Journal of Haematology, 176(5), 728–742. https://doi.org/10.1111/bjh.14492
Da Vià, M. C., Lionetti, M., Marella, A., Matera, A., Travaglino, E., Signaroldi, E., Galbussera, A. A., Lucca, U., Mandelli, S., Riva, E., Tettamanti, M., Pettine, L., Pompa, A., Baldini, L., Neri, A., Della Porta, M. G., & Bolli, N. (2022). MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Advances, 6(21), 5702–5706. https://doi.org/10.1182/bloodadvances.2021006498
Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M. V., Richardson, P.,…International Myeloma Working Group. (2023). Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group. The Lancet Oncology, 24(7), e293–e311. https://doi.org/10.1016/S1470-2045(23)00223-1
Dispenzieri, A. (2023). POEMS syndrome: Update on diagnosis, risk-stratification, and management. American Journal of Hematology, 98(12), 1934–1950. https://doi.org/10.1002/ajh.27081
Einarsson Long, T., Rognvaldsson, S., Thorsteinsdottir, S., Sverrisdottir, I. S., Eythorsson, E., Oskarsson, J. T., Indridason, O. S., Palsson, R., Aspelund, T., Vidarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurdardottir, M., Thorsteinsdottir, I., Olafsson, I., Thordardottir, A. R., Jonsson, A., Gislason, G., Olafsson, A., Hultcrantz, M.,…Kristinsson, S. Y. (2025). New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. JAMA Oncology, 11(7), 753–761. https://doi.org/10.1001/jamaoncol.2025.1285
El-Khoury, H., Lee, D. J., Alberge, J. B., Redd, R., Cea-Curry, C. J., Perry, J., Barr, H., Murphy, C., Sakrikar, D., Barnidge, D., Bustoros, M., Leblebjian, H., Cowan, A., Davis, M. I., Amstutz, J., Boehner, C. J., Lightbody, E. D., Sklavenitis-Pistofidis, R., Perkins, M. C.,…Ghobrial, I. M. (2022). Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A multicentre cohort study. The Lancet Haematology, 9(5), e340–e349. https://doi.org/10.1016/S2352-3026(22)00069-2
Eythorsson, E., Rognvaldsson, S., Thorsteinsdottir, S., Einarsson Long, T., Reed, E. R., Sigurdardottir, G. A., Vidarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurdardottir, M., Olafsson, I., Thorsteinsdottir, I., Sveinsdottir, S. V., Sigurdsson, F., Thordardottir, A. R., Palsson, R., Indridason, O. S., Jonsson, A., Gislason, G. K.,…Kristinsson, S. Y. (2024). Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance: A cohort study nested in a clinical trial. Annals of Internal Medicine, 177(4), 449–457. https://doi.org/10.7326/M23-2540
Go, R. S., & Rajkumar, S. V. (2018). How I manage monoclonal gammopathy of undetermined significance. Blood, 131(2), 163–173. https://doi.org/10.1182/blood-2017-09-807560
Gonsalves, W. I., & Rajkumar, S. V. (2022). Monoclonal gammopathy of undetermined significance. Annals of Internal Medicine, 175(12), ITC177–ITC192. https://doi.org/10.7326/AITC202212200
Gozzetti, A., Guarnieri, A., Zamagni, E., Zakharova, E., Coriu, D., Bittrich, M., Pika, T.,…Jurczyszyn, A. (2022). Monoclonal gammopathy of renal significance: Real-world data on outcomes and prognostic factors. American Journal of Hematology, 97(7), 877–884. https://doi.org/10.1002/ajh.26566
Iberri, D., & Liedtke, M. (2024). MGUS: Where do we stand today? Hematology: American Society of Hematology Education Program, 2024(1), 482–488. https://doi.org/10.1182/hematology.2024000572
Jain, A., Haynes, R., Lothari, J., Soares, M., & Ramasamy, K. (2019). Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Advances, 3(15), 2409–2423. https://doi.org/10.1182/bloodadvances.2019031914
Kang, K. W., Song, J. E., Lee, B. H., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Choi, C. W., Park, Y., & Kim, B. S. (2021). A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Scientific Reports, 11(1), 18449. https://doi.org/10.1038/s41598-021-97664-y
Kapoor, P., & Rajkumar, S. V. (2022). Cardiovascular associations with monoclonal gammopathy of undetermined significance: Real or coincidental? JACC: CardioOncology, 4(3), 323–325. https://doi.org/10.1016/j.jaccao.2022.07.002
Karam, S., Haidous, M., Dalle, I. A., Dendooven, A., Moukalled, N., Van Craenenbroeck, A., Bazarbachi, A., & Sprangers, B. (2023). Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment. Critical Reviews in Oncology/Hematology, 183, 103926. https://doi.org/10.1016/j.critrevonc.2023.103926
Khwaja, J., D’Sa, S., Minnema, M. C., Kersten, M. J., Wechalekar, A., & Vos, J. M. (2022). IgM monoclonal gammopathies of clinical significance: Diagnosis and management. Haematologica, 107(9), 2037–2050. https://doi.org/10.3324/haematol.2022.280953
Kleinstern, G., Larson, D. R., Allmer, C., Norman, A. D., Muntifering, G., Sinnwell, J., Visram, A., Rajkumar, S. V., Dispenzieri, A., Kyle, R. A., Slager, S. L., Kumar, S., & Vachon, C. M. (2022). Body mass index associated with monoclonal gammopathy of undetermined significance progression in Olmsted County, Minnesota. Blood Cancer Journal, 12(4), 67. https://doi.org/10.1038/s41408-022-00659-9
Klomjit, N., Leung, N., Fervenza, F. C., Sethi, S., & Zand, L. (2020). Rate and predictors of finding monoclonal gammopathy of renal significance lesions on kidney biopsy in patients with monoclonal gammopathy. Journal of the American Society of Nephrology, 31(10), 2400–2411.
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 378(3), 241–249. https://doi.org/10.1056/NEJMoa1709974
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y. L., Kapoor, P., Leung, N., Go, R. S., Lin, Y., Kourelis, T. V., Warsame, R., Lust, J. A.,…Kumar, S. K. (2018). Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 8(6), 59. https://doi.org/10.1038/s41408-018-0077-4
Landgren, O., Kristinsson, S. Y., Goldin, L. R., Caporaso, N. E., Blimark, C., Mellqvist, U. H., Wahlin, A., Björkholm, M., & Turesson, I. (2009). Risk of plasma cell and lymphoproliferative disorders among first-degree relatives of patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 114(4), 791–795. https://doi.org/10.1182/blood-2008-12-191676
Lee, D. J., El-Khoury, H., Tramontano, A. C., Alberge, J. B., Perry, J., Davis, M. I., Horowitz, E., Redd, R., Sakrikar, D., Barnidge, D., Perkins, M. C., Harding, S., Mucci, L., Rebbeck, T. R., Ghobrial, I. M., & Marinac, C. R. (2024). Mass spectrometry–detected monoclonal gammopathy of undetermined significance is associated with obesity and other modifiable risk factors in a high-risk population. Blood Advances, 8(7), 1737–1746. https://doi.org/10.1182/bloodadvances.2023010843
Leung, N., Bridoux, F., Batuman, V., Chaidos, A., Cockwell, P., D’Agati, V. D., Dispenzieri, A., Fervenza, F. C., Fermand, J.-P., Gibbs, S., Gillmore, J. D., Herrera, G. A., Jaccard, A., Jevremovic, D., Kastritis, E., Kukreti, V., Kyle, R. A., Lachmann, H. J., Larsen, C. P., Ludwig, H.,…Nasr, S. H. (2019). The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 15(1), 45–59. https://doi.org/10.1038/s41581-018-0077-4
Leung, N., Bridoux, F., & Nasr, S. H. (2021). Monoclonal gammopathy of renal significance. The New England Journal of Medicine, 384(20), 1931–1941. https://doi.org/10.1056/NEJMra1810907
Li, Y., Hsu, S. H., Wang, R., Theprungsirikul, P., Neparidze, N., Chang, S. H., & Wang, S. Y. (2024). Associations between patient characteristics and progression to multiple myeloma among patients with monoclonal gammopathy of undetermined significance: A systematic review. Clinical Lymphoma, Myeloma & Leukemia. Advance online publication.
Liu, Y., & Parks, A. L. (2025). Diagnosis and management of monoclonal gammopathy of undetermined significance: A review. JAMA Internal Medicine, 185(4), 450–456. https://doi.org/10.1001/jamainternmed.2024.8124
Lomas, O. C., Mouhieddine, T. H., Tahri, S., & Ghobrial, I. M. (2020). Monoclonal gammopathy of undetermined significance—not so asymptomatic after all. Cancers, 12(6), 1554. https://doi.org/10.3390/cancers12061554
Lyle, M. A., Bhatia, S., Fenstad, E., Schroeder, D., McCully, R. B., Lacy, M. Q., & Feyereisn, W. (2022). Association of pulmonary hypertension and monoclonal gammopathy of undetermined significance. Advances in Hematology, 2022, 8918959. https://doi.org/10.1155/2022/8918959
Merz, M., Hielscher, T., Hoffmann, K., Seckinger, A., Hose, D., Raab, M. S., Hillengass, J., Jauch, A., & Goldschmidt, H. (2018). Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukemia, 32(12), 2717–2719. https://doi.org/10.1038/s41375-018-0202-1
Moreno, D. F., Rosiñol, L., Cibeira, M. T., Bladé, J., & Fernández de Larrea, C. (2021). Treatment of patients with monoclonal gammopathy of clinical significance. Cancers, 13(20), 5131. https://doi.org/10.3390/cancers13205131
Mouhieddine, T. H., Weeks, L. D., & Ghobrial, I. M. (2019). Monoclonal gammopathy of undetermined significance. Blood, 133(23), 2484–2494. https://doi.org/10.1182/blood.2019846782
Oganesyan, A., Gregory, A., Malard, F., Ghahramanyan, N., Mohty, M., Kazandjian, D., Mekinian, A., & Hakobyan, Y. (2022). Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment. Frontiers in Immunology, 13, 1045002. https://doi.org/10.3389/fimmu.2022.1045002
Pérez-Persona, E., Mateo, G., García-Sanz, R., Mateos, M. V., de Las Heras, N., de Coca, A. G., Hernández, J. M., Galende, J., Martín-Nuñez, G., Bárez, A., Alonso, J. M., Martín, A., López-Berges, C., Orfao, A., San Miguel, J. F., & Vidriales, M. B. (2010). Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. British Journal of Haematology, 148(1), 110–114. https://doi.org/10.1111/j.1365-2141.2009.07929.x
Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., 3rd, Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 106(3), 812–817. https://doi.org/10.1182/blood-2005-03-1038
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., Jagannath, S.,…Miguel, J. F. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology, 15(12), e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Ríos-Tamayo, R., Paiva, B., Lahuerta, J. J., López, J. M., & Duarte, R. F. (2022). Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal. Cancers, 14(21), 5247. https://doi.org/10.3390/cancers14215247
Sidiqi, M. H., Aljama, M., Kumar, S. K., Jevremovic, D., Buadi, F. K., Warsame, R., Lacy, M. Q., Dingli, D., Gonsalves, W. I., Fonder, A. L., Hobbs, M. A., Hwa, Y. L., Kapoor, P., Kourelis, T., Leung, N., Muchtar, E., Lust, J. A., Kyle, R. A., Go, R. S., Rajkumar, V. S.,…Dispenzieri, A. (2020). The role of bone marrow biopsy in patients with plasma cell disorders: Should all patients with a monoclonal protein be biopsied? Blood Cancer Journal, 10(5), 52. https://doi.org/10.1038/s41408-020-0319-0
Sigurbergsdóttir, A. Ý., Rögnvaldsson, S., Thorsteinsdóttir, S., Sverrisdóttir, I., Sigurðardóttir, G. Á., Viðarsson, B., Önundarson, P. T., Agnarsson, B. A., Sigurðardóttir, M., Þorsteinsdóttir, I., Ólafsson, Í., Þórðardóttir, Á. R., Gíslason, G. K., Ólafsson, A., Hultcrantz, M., Durie, B. G. M., Harding, S., Landgren, O., Löve, T. J., & Kristinsson, S. Y. (2023). Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: Results from the population-based iStopMM study. Haematologica, 108(12), 3392–3398. https://doi.org/10.3324/haematol.2023.283191
Stern, S., Chaudhuri, S., Drayson, M., Henshaw, S., Karunanithi, K., Willis, F., & Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum. (2023). Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. British Journal of Haematology, 202(4), 734–744. https://doi.org/10.1111/bjh.18866
Testa, U., Leone, G., Pelosi, E., Castelli, G., & De Stefano, V. (2024). Is it possible to predict tumor progression through genomic characterization of monoclonal gammopathy and smoldering multiple myeloma?. Mediterranean Journal of Hematology and Infectious Diseases, 16(1), e2024044. https://doi.org/10.4084/MJHID.2024.04
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., Munshi, M., Chan, G., Dubeau, T., Raje, N., Yee, A., O’Donnell, E., Hunter, Z. R., & Castillo, J. J. (2018). Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström Macroglobulinemia. Journal of Clinical Oncology, 36(27), 2755–2761. https://doi.org/10.1200/JCO.2018.78.6426
Turesson, I., Kovalchik, S. A., Pfeiffer, R. M., Kristinsson, S. Y., Goldin, L. R., Drayson, M. T., & Landgren, O. (2014). Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood, 123(3), 338–345. https://doi.org/10.1182/blood-2013-05-505487
Visentin, A., Pravato, S., Castellani, F., Campagnolo, M., Angotzi, F., Cavarretta, C. A., Cellini, A., Ruocco, V., Salvalaggio, A., Tedeschi, A., Trentin, L., & Briani, C. (2022). From biology to treatment of monoclonal gammopathies of neurological significance. Cancers, 14(6), 1562. https://doi.org/10.3390/cancers14061562
Zuern, K., Hielscher, T., Werly, A., Breitkreutz, I., Sauer, S., Raab, M. S., Müller-Tidow, C., Goldschmidt, H., & Mai, E. K. (2024). Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance. Blood Cancer Journal, 14(1), 148. https://doi.org/10.1038/s41408-024-01126-3
